Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2021

View Archived Issues

Intratumoral cytokine-encoding mRNA mixture induces antitumor immunity in tumor models

BP-1200_002, a novel anti-CD73 antibody that improves efficacy of cancer immunotherapy

Development of NTC-001, a first-in-class humanized antibody targeting CXCL1

New humanized Col6a1-mutated knock-in mouse model of collagen VI-related muscular dystrophy

Shanghai Zheye Biotechnology divulges G12C mutant GTPase KRAS inhibitors

Peking University presents new boron-carrying agents

Cytomegalovirus DNA polymerase inhibitors discovered at the University of Alberta

New KDM1A inhibitors discovered at Shenyang Pharmaceutical University

Assessing pharmacologic activity of PD(L)-1 MAb therapeutics in tumors by target pharmacodynamics

Targeting KIR3DS1/HLA-F axis as new therapeutic strategy against human adenovirus infections

Intranasal subunit SARS-CoV-2 vaccines elicit mucosal and systemic immunity in vivo

Shionogi licenses S-365598 to ViiV for use in ultra long-acting HIV regimens

Mitochon announces funding to support development of MP-201 for TBI

RARA identified as a druggable target for pediatric acute myeloid leukemia

Point Biopharma reports preclinical data on FAP-alpha inhibitor program

SBIR grant supports Senti's development of CAR-NK cell therapy SENTI-202 for AML

Gamida Cell announces new NK cell construct development programs

Interim data on psilocybin plus NAC in rodent model of mild TBI and PTSD

LG Chem selects preclinical candidate from PD-L1/XT program with Avacta

Close SARS-CoV-2 relative strengthens natural origin theory

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...